Comparison of the expression levels of molecular markers among the peripheral area and central area of primary tumor and metastatic lymph node tumor in patients with squamous cell carcinoma of the lung

[1]  A. Ochiai,et al.  Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma , 2015, Gastric Cancer.

[2]  A. Ochiai,et al.  Immunophenotypic features of metastatic lymph node tumors to predict recurrence in N2 lung squamous cell carcinoma , 2014, Cancer science.

[3]  R. Rocha,et al.  EGFR expression in vulvar cancer: clinical implications and tumor heterogeneity. , 2014, Human pathology.

[4]  Alexandar Tzankov,et al.  Putative Stem Cell Markers in Non–Small-Cell Lung Cancer: A Clinicopathologic Characterization , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  H. Ohmatsu,et al.  Identification of Biological Properties of Intralymphatic Tumor Related to the Development of Lymph Node Metastasis in Lung Adenocarcinoma , 2013, PloS one.

[6]  D. Thickett,et al.  Epithelial–mesenchymal transition in lung development and disease: does it exist and is it important? , 2013, Thorax.

[7]  van der Bernard Laan,et al.  Lack of claudin-7 is a strong predictor of regional recurrence in oral and oropharyngeal squamous cell carcinoma. , 2013, Oral oncology.

[8]  A. Naik,et al.  Correlation of breast cancer axillary lymph node metastases with stem cell mutations. , 2013, JAMA surgery.

[9]  Junjie Chen,et al.  The Prognostic Value of SOX2 Expression in Non-Small Cell Lung Cancer: A Meta-Analysis , 2013, PloS one.

[10]  S. Baldus,et al.  High EpCAM expression is linked to proliferation and lauren classification in gastric cancer , 2013, BMC Research Notes.

[11]  Wun-Jae Kim,et al.  Combined aberrant expression of E-cadherin and S100A4, but not β-catenin is associated with disease-free survival and overall survival in colorectal cancer patients , 2013, Diagnostic Pathology.

[12]  G. Sauter,et al.  Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer. , 2013, Lung cancer.

[13]  Y. Hu,et al.  Metastatic Lymph Node CHIP Expression is a Potential Prognostic Marker for Resected Esophageal Squamous Cell Carcinoma Patients , 2013, Annals of Surgical Oncology.

[14]  H. Dienemann,et al.  Ly6/uPAR-Related Protein C4.4A as a Marker of Solid Growth Pattern and Poor Prognosis in Lung Adenocarcinoma , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[16]  A. Ochiai,et al.  Recruitment of Podoplanin Positive Cancer-Associated Fibroblasts in Metastatic Lymph Nodes Predicts Poor Prognosis in Pathological N2 Stage III Lung Adenocarcinoma , 2012, Annals of Surgical Oncology.

[17]  Y. Doki,et al.  C4.4A is associated with tumor budding and epithelial–mesenchymal transition of colorectal cancer , 2012, Cancer science.

[18]  M. Tsuboi,et al.  Alveolar space filling ratio as a favorable prognostic factor in small peripheral squamous cell carcinoma of the lung. , 2011, Lung cancer.

[19]  M. Fan,et al.  The expression of E-cadherin at the invasive tumor front of oral squamous cell carcinoma: immunohistochemical and RT-PCR analysis with clinicopathological correlation. , 2009, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[20]  R. Berardi,et al.  Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options , 2007, British Journal of Cancer.

[21]  Adam Elzagheid,et al.  E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome. , 2006, World journal of gastroenterology.

[22]  A. Italiano,et al.  Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  R. Berardi,et al.  Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Wiseman,et al.  Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry , 2004, Modern Pathology.

[25]  J. Bergh,et al.  HER-2/neu (c-erbB-2) Evaluation in Primary Breast Carcinoma by Fluorescent In Situ Hybridization and Immunohistochemistry With Special Focus on Intratumor Heterogeneity and Comparison of Invasive and In Situ Components , 2004, Applied immunohistochemistry & molecular morphology : AIMM.

[26]  Y. Nishiwaki,et al.  Clinicopathologic Characteristics of Peripheral Squamous Cell Carcinoma of the Lung , 2003, The American journal of surgical pathology.

[27]  J. Schneider,et al.  Histologic Grade and CD44 Are Independent Predictors of Axillary Lymph Node Invasion in Early (T1) Breast Cancer , 1999, Tumor Biology.

[28]  A. D. De Marzo,et al.  CD44 and CD44v6 downregulation in clinical prostatic carcinoma: Relation to Gleason grade and cytoarchitecture , 1998, The Prostate.

[29]  K. Friedrichs,et al.  CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. , 1995, Cancer research.

[30]  E. Santoni-Rugiu,et al.  Changes in epidermal growth factor receptor expression during chemotherapy in non-small cell lung cancer , 2013, Cancer Chemotherapy and Pharmacology.

[31]  K. O'Byrne,et al.  EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. , 2012, The Lancet. Oncology.

[32]  K. Polyak,et al.  Tumor heterogeneity: causes and consequences. , 2010, Biochimica et biophysica acta.